Clinical Trials Browser

Lymphoma × NPI 2358 × Clear all

NCT00322608 2011-01-10

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

Lymphoma, Neoplasms